A clinical phase I trial was designed to evaluate whether the intravenous infusion of PCZ increased the number of cetuximab‐binding sites on the cell surface.[11a] Another phase Ib trial showed that the combination of cetuximab and PCZ at concentrations that could inhibit dynamin exhibited no serious adverse events.[11b] These studies demonstrated the potential effectiveness of this combination strategy in the context of CRC. This evidence concerns the gene DNM1 and colorectal carcinoma.